SARASOTA, Fla., Aug 10, 2000 (BUSINESS WIRE) --  DNAPrint genomics, Inc., (Pink
Sheets:DNAP), a Sarasota, Florida based genomics company, announced today that
Chief Scientific Officer, Dr. Tony Frudakis, was featured on CEOcast.com, the
premier source of original and syndicated streaming broadcast interviews of
Chief Executive Officers at news-making public and private companies.
 
The live audio interview can be accessed on the Internet at
ceocast.com.
 
Referring to the potential of the genomics industry, Dr. Frudakis says, "Due to
the power of the human genome project and the tools that have come from it,
population-wide and systematic studies of genotype-phenotype relationships are
possible for the first time in human history."
 
Dr. Frudakis explains, "We believe that our informatics platform will constitute
the operating system for personalized medicine in the future. The potential for
diagnomics products could easily exceed that for traditional protein-based or
immunological-based diagnostic products. First and foremost, diagnomics products
will help to prevent disease (by avoiding suboptimal patient-drug combinations)
not just report disease after it happens. Secondly, diagnomics products have a
greater market (especially as baby boomers age). Virtually every person who uses
  (COMTEX)     B: DNAPrint genomics Dr. Tony Frudakis Featured on CEOcast.c
B: DNAPrint genomics Dr. Tony Frudakis Featured on CEOcast.com
 
SARASOTA, Fla., Aug 10, 2000 (BUSINESS WIRE) --  DNAPrint genomics, Inc., (Pink
Sheets:DNAP), a Sarasota, Florida based genomics company, announced today that
Chief Scientific Officer, Dr. Tony Frudakis, was featured on CEOcast.com, the
premier source of original and syndicated streaming broadcast interviews of
Chief Executive Officers at news-making public and private companies.
 
The live audio interview can be accessed on the Internet at
ceocast.com.
 
Referring to the potential of the genomics industry, Dr. Frudakis says, "Due to
the power of the human genome project and the tools that have come from it,
population-wide and systematic studies of genotype-phenotype relationships are
possible for the first time in human history."
 
Dr. Frudakis explains, "We believe that our informatics platform will constitute
the operating system for personalized medicine in the future. The potential for
diagnomics products could easily exceed that for traditional protein-based or
immunological-based diagnostic products. First and foremost, diagnomics products
will help to prevent disease (by avoiding suboptimal patient-drug combinations)
not just report disease after it happens. Secondly, diagnomics products have a
greater market (especially as baby boomers age). Virtually every person who uses
(prescription medication) is a potential customer."
 
About CEOcast
 
Organized by industry, its analysts average more than 15 years' experience
covering and evaluating Wall Street's leading companies. CEOcast's programming
is distributed to millions of online investors at more than 700 financial Web
sites as well as to more than 20,000 portfolio managers, buy-side analysts and
traders at more than 3,300 North American institutions. Content is also
disseminated to more than 7,000 investment research professionals representing
more then 425 institutions. All content is copyrighted to protect the company's
licensing partners.
 
About DNAPrint genomics
 
DNAPrint genomics, Inc. provides practitioners of genomic research and
personalized medicine with a comprehensive system for complex trait dissection
and patient classification. DNAPrint genomics Inc. was founded by a group of
scientists with research and commercial experience in high-level mathematical
modeling, programming and molecular genetics. For more information about the
company, please visit www.dnaprint.com.
 
Except for factual statements made herein, the information contained in this
press release consists of forward-looking statements that involve risks and
uncertainties. The Company's actual results could differ materially from those
contained in such statements. Factors that could cause or contribute to such
differences include unexpected shortages of critical components, rescheduling or
cancellation of customer orders, the timing and market acceptance of new product
introductions by the Company and its competitors, and general competition and
price pressures in the marketplace.
 
 
 CONTACT:          For scientific inquiries:
                   DNAPrint genomics, Inc., Sarasota
                   Dr. Tony Frudakis, 941/351-4543
                   or
                   All other inquiries:
                   Richard Craig Hall, 941/341-0136